Engineered RNA Modification Recognition

工程化 RNA 修饰识别

基本信息

批准号：
10697237
负责人：
Zachary Miles
金额：
$ 34.77万
依托单位：
ALIDA BIOSCIENCES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-01 至 2023-10-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10697237
关键词：
Acceleration Affinity Aging Alternative Splicing Antibodies Award Bar Codes Binding Bioinformatics Biological Biological Assay Biological Sciences Biology Biopsy Cells Chemicals Chemotherapy-Oncologic Procedure Clinical Clinical Trials Code Coupled DNA Dedications Dependence Detection Directed Molecular Evolution Disease Disease Progression Drug resistance Elements Engineering Evolution Exhibits Funding Gene Expression Genetic Code Genetic Transcription Grant Health Knowledge Libraries Ligands Malignant Neoplasms Messenger RNA Methods Modification Molecular Mutation Needle biopsy procedure Outcome Pathway interactions Performance Phase Play Process Property Protein Engineering Proteins Publications RNA RNA Folding RNA Sequences RNA-Protein Interaction Reader Reading Reagent Regulator Genes Reproducibility Research Research Personnel Role Sampling Science Small Business Innovation Research Grant Specificity Technology Testing Therapeutic Time Transcript Translations Variant Vertebral column Virus Diseases Work Yeasts clinical biomarkers clinically relevant cloud based commercialization data handling design diagnostic biomarker drug development epitranscriptome epitranscriptomics improved molecular recognition monomer nano next generation novel novel diagnostics nucleobase product development programs rapid growth scaffold success symposium technology platform trafficking tumor tumor progression user-friendly

项目摘要

Abstract Alida Biosciences Inc is developing a commercial platform for the analysis of the epitranscriptome, which is the totality of chemical modifications applied naturally to RNA to regulate possibly all aspects of RNA biology: transcription (mods are installed co-transcriptionally), translation, transcript lifetime, trafficking, alternative splicing, RNA folding, RNA–protein interactions, and more. The field of epitranscriptomics has seen rapid growth, motivated by the significance of this biology and the emerging opportunities to use RNA modifications as diagnostic biomarkers and to intervene in epitranscriptomic pathways as a promising novel paradigm in drug development, especially in cancer chemotherapy. Alida’s platform technology will make epitranscriptomics more accessible by offering a user-friendly workflow, integrated process controls, and cloud-based data handling and bioinformatics. In this SBIR grant, we seek to develop engineered RNA modification binding agents for integration into our platform. The enhanced properties of the novel agents will be optimized specifically for our platform to maximize sensitivity and selectivity, which is especially significant for high-value clinical samples in which only sub-nanogram quantities of RNA are likely to be available: needle biopsies, FFPE samples, and others.

抽象的 Alida Biosciences Inc 正在开发一个用于分析表观转录组的商业平台，该平台是自然应用于 RNA 的化学修饰的整体，可能调节 RNA 生物学的所有方面：转录（模组以共转录方式安装）、翻译、转录寿命、贩运、替代剪接、RNA 折叠、RNA-蛋白质相互作用等表观转录组学领域已经快速发展。受到这种生物学的重要性以及利用 RNA 修饰作为新出现的机会的激励诊断生物标志物并干预表观转录组通路，作为药物领域有前途的新范例尤其是在癌症化疗方面的发展，Alida的平台技术将使表观转录组学更加丰富。通过提供用户友好的工作流程、集成的过程控制和基于云的数据处理和在这项 SBIR 资助中，我们寻求开发工程化的 RNA 修饰结合剂。集成到我们的平台中。新型药物的增强特性将专门针对我们的进行优化。平台可最大限度地提高灵敏度和选择性，这对于高价值临床样本尤其重要可能只能获得亚纳克量的 RNA：针吸活检、FFPE 样本和其他的。